The aim of this study is to make evidence-based data for developing a traditional Korean medicine clinical practice guideline for acute bronchitis. Methods: We searched 3 international databases(PubMed, EMBASE, CENTRAL) and 7 domestic databases (KoreaMed, Kmbase, NDSL, KISS, KISTI, OASIS, KoreaTK) to identify randomized controlled trials (RCTs) of acute bronchitis using medicine in recent 10 years. The chosen trials were analyzed by their study design, age range, intervention group, control group, primary and second outcome measure, inclusion and exclusion of participants and adverse events. Results: 15 RCTs are finally included in this study and most of their medications are herbal medicine. For diagnosis and outcome measure of acute bronchitis, Bronchitis Severity Score(BSS) was mostly used. Other measurements eligible are coughing fits, quality of life scale, sputum viscosity, change of individual symptoms and patient's satisfaction. Test duration was for average 7days and safety assessment was held by recording adverse events. Except for anti-inflammatory and antibiotic trials, all medications are found to be effective and well-tolerated. General risk of bias of chosen trials is evaluated low. Conclusions: A well designed clinical trials for traditional Korean medicine of acute bronchitis is needed and this study is expected to make it available. 
. 하지만 약 65%의 성인 환자에게 항생제 가 처방되고 있어 항생제의 오남용에 대한 사회적 문제가 심각한 상황이다 8) . 2) concomitant bacterial infection 3) elevated body temperature(>39.5°C rectally or >39.0°C axillary or otic) 4) active cigarette smoking > 1 pack per day 5) hypersensitivity to the trial medication 6) inflammatory gastrointestinal or hepatic disease or inflammation of the gallbladder or bile duct, history or presence of clinically relevant cardiovascular, renal, metabolic, hematological, dermatologic, neurological, psychiatric, systemic or infectious disease 7) pregnancy or breast feeding, women of childbearing potential without highly effective contraception (failure rate<1%) 8) participation in a clinical research study within the last 6 weeks 9) evidence or suspicion of non-compliance, inability to provide informed consent.
(105) 3) BSS≥5 points at screening 1) treatment with antibiotics, bronchodilators or glucocorticoids during the last 4 weeks, or with analgetics, secretolytics, mucolytics or antitussive during the last 7 days prior to study inclusion 2) indication for treatment with antibiotics 3) allergic asthma, tendency to bleed, severe heart, renal or liver diseases and⁄or immunosuppression, known hypersensitivity against P. sidoides, chronic obstructive pulmonary disease and pregnancy.
Kamin W'
double-blind randomized clinical trial 1) aged 1-18 years suffering from acute bronchitis 2) symptoms starting 48 hours prior to inclusion into the study 3) BSS≥5points at screening 1) treatment with antibiotics 2) allergic asthma, COPD, tendency to bleed, severe heart, renal or liver diseases and/or immunosuppression;
3) known hypersensitivity against Pelargonium sidoides 4) pregnancy 2) allergic asthma, chronic obstructive pulmonary disease, tendency to bleed, severe heart, renal or liver diseases and/or immunosuppression 3) known hypersensitivity to Pelargonium sidoides 4) pregnancy Kemmerich B(2007) double-blind, placebo controlled, multicenter Phase IV study 1) at least 18 years of age, 2) ≥10 coughing fits during the day 3) onset of bronchial mucus production with impaired ability to cough up at a maximum of 2 days prior to recruitment 4) BSS ≥ 5points at screening 1) pregnancy, no contraception for women of child bearing age and lactation for females 2) the principal ones being concomitant fever(> 39 °C)
3) pneumonia, history of chronic bronchial or pulmonary disease such as chronic bronchitis, chronic obstructive pulmonary disease (including acute episode), bronchiectasis, bronchial asthma, mucoviscidosis, history of clinically relevant chronic cardiovascular, kidney, gastrointestinal or liver disease, known hypersensitivity to one or more of the active or inactive ingredients of the investigational product, malignant growth, or any severe somatopathic, neurological and/or psychiatric disease.
(106) 2) presenting with a productive cough of 2 weeks duration 1) another potential explanation for cough (history of chronic bronchitis, allergic rhinitis, sinusitis, asthma or gastric reflux),
2) serious medical comorbidity (heart disease or diabetes), penicillin allergy, antibiotic use in the preceding 2 weeks or a concurrent infection (including tuberculosis) requiring antibiotic treatment. 
